» Articles » PMID: 36584301

Mechanism of PKCε Regulation of Cardiac GIRK Channel Gating

Overview
Specialty Science
Date 2022 Dec 30
PMID 36584301
Authors
Affiliations
Soon will be listed here.
Abstract

G-protein-gated inwardly rectifying potassium (GIRK) channel activity is regulated by the membrane phospholipid, phosphatidylinositol-4,5-bisphosphate (PI 4,5P). Constitutive activity of cardiac GIRK channels in atrial myocytes, that is implicated in atrial fibrillation (AF), is mediated via a protein kinase C-ε (PKCε)-dependent mechanism. The novel PKC isoform, PKCε, is reported to enhance the activity of cardiac GIRK channels. Here, we report that PKCε stimulation leads to activation of GIRK channels in mouse atria and in human stem cell-derived atrial cardiomyocytes (iPSCs). We identified residue GIRK4(S418) which when mutated to Ala abolished, or to Glu, mimicked the effects of PKCε on GIRK currents. PKCε strengthened the interactions of the cardiac GIRK isoforms, GIRK4 and GIRK1/4 with PIP, an effect that was reversed in the GIRK4(S418A) mutant. This mechanistic insight into the PKCε-mediated increase in channel activity because of GIRK4(S418) phosphorylation, provides a precise druggable target to reverse AF-related pathologies due to GIRK overactivity.

Citing Articles

Angiotensin receptors and α-adrenergic receptors regulate native IK and phosphorylation-deficient GIRK4 (S418A) channels through different PKC isoforms.

Inderwiedenstrasse L, Kienitz M Pflugers Arch. 2024; 476(7):1041-1064.

PMID: 38658400 DOI: 10.1007/s00424-024-02966-5.


The W101C Mutation Induces Slower Pacing by Constitutively Active GIRK Channels in hiPSC-Derived Cardiomyocytes.

Kayser A, Dittmann S, Saric T, Mearini G, Verkerk A, Schulze-Bahr E Int J Mol Sci. 2023; 24(20).

PMID: 37894977 PMC: 10607318. DOI: 10.3390/ijms242015290.


PI(4,5)P2 regulates the gating of NaV1.4 channels.

Gada K, Kamuene J, Chandrashekar A, Kissell R, Yauch A, Plant L J Gen Physiol. 2023; 155(6).

PMID: 37043561 PMC: 10103707. DOI: 10.1085/jgp.202213255.

References
1.
Andrade J, Khairy P, Dobrev D, Nattel S . The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014; 114(9):1453-68. DOI: 10.1161/CIRCRESAHA.114.303211. View

2.
Lakatta E, Levy D . Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation. 2003; 107(2):346-54. DOI: 10.1161/01.cir.0000048893.62841.f7. View

3.
Gazgalis D, Cantwell L, Xu Y, Thakur G, Cui M, Guarnieri F . Use of a Molecular Switch Probe to Activate or Inhibit GIRK1 Heteromers In Silico Reveals a Novel Gating Mechanism. Int J Mol Sci. 2022; 23(18). PMC: 9502415. DOI: 10.3390/ijms231810820. View

4.
Takemoto Y, Slough D, Meinke G, Katnik C, Graziano Z, Chidipi B . Structural basis for the antiarrhythmic blockade of a potassium channel with a small molecule. FASEB J. 2017; 32(4):1778-1793. PMC: 5893172. DOI: 10.1096/fj.201700349R. View

5.
Stanfield P . Homomers of Kir.3.4 in atrial myocytes: their relevance to atrial fibrillation. J Physiol. 2007; 585(Pt 1):1. PMC: 2375452. DOI: 10.1113/jphysiol.2007.145912. View